Overview

Open-label Study on Treatment of Primary Aldosteronism With Everolimus

Status:
Completed
Trial end date:
2018-06-25
Target enrollment:
Participant gender:
Summary
The overall objective is to evaluate everolimus as an aldosterone-lowering drug in the treatment of primary hyperaldosteronism.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Everolimus
Sirolimus